Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZIOPHARM Oncology has received an allowance from the European Patent Office for patent application number 05 821 125.1 for Palifosfamide.
Subscribe to our email newsletter
The patent covers pharmaceutical compositions of a DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos or ZIO-201) and their use in treating cancer.
The company has also received Australian patent covering a crystalline form of darinaparsin (Zinapar or ZIO-101), pharmaceutical compositions containing such compounds, and methods to use in cancer treatment.
ZIOPHARM chief legal officer Caesar Belbel said that both the allowance and recent issuance are evidence of their continued execution of global development programs.